Wide Ranks

GMAB

Genmab A/S

21.16

Top Statistics
Market Cap 13 B Forward PE 13.39 Revenue Growth 17.60 %
Current Ratio 5.17 Trailing PE 20.75 Earnings Growth -38.00 %
Profit Margins 23.70 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.19 Enterprise / Revenue -0.7550 Price To Sales Trailing12 Months 0.6773
Profitability
Profit Margins 23.70 % Operating Margins 38.25 %
Balance Sheet
Total Cash 17 B Total Cash Per Share 272.67 Total Debt 987 M
Total Debt To Equity 3.09 Current Ratio 5.17 Book Value Per Share 502.60
All Measures
Short Ratio 152.00 % Message Board Id finmb_665704 Shares Short Prior Month 1 M
Return On Equity 0.1492 City Copenhagen Uuid 5594dda7-7736-3abc-bcfd-5fa676c317ff
Previous Close 20.65 First Trade Date Epoch Utc 1 B Book Value 502.60
Beta 0.8590 Total Debt 987 M Volume 785831
Price To Book 0.0421 Last Split Date 1 B Fifty Two Week Low 20.34
Total Cash Per Share 272.67 Total Revenue 19 B Shares Short Previous Month Date 1 B
Target Median Price 35.50 Max Age 86400 Recommendation Mean 2.33
Sand P52 Week Change 0.3133 Operating Margins 38.25 % Target Mean Price 36.56
Net Income To Common 4 B Short Percent Of Float 0.0036 Implied Shares Outstanding 639 M
Trailing Peg Ratio 73.57 % Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 17 B Next Fiscal Year End 1 B
Revenue Per Share 30.70 Held Percent Insiders 0.0001 Ebitda Margins 34.54 %
Trailing PE 20.75 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 20.65 Target Low Price 23.50 Gmt Off Set Milliseconds -18000000
Fifty Day Average 22.83 Open 20.86 Free Cashflow 5 B
Dividend Yield 0.00 % Return On Assets 0.1095 Time Zone Short Name EST
Trailing Eps 1.02 Day Low 20.84 Address1 Carl Jacobsens Vej 30
Shares Outstanding 635 M Price Hint 2 Target High Price 50.00
Website https://www.genmab.com 52 Week Change -0.3306 Average Volume 1 M
Earnings Quarterly Growth -39.80 % Forward Eps 1.40 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 515.30 % Last Split Factor 5:1
Regular Market Day High 21.17 Is_sp_500 False Profit Margins 23.70 %
Debt To Equity 3.09 Fifty Two Week High 32.88 Day High 21.17
Shares Short 2 M Regular Market Open 20.86 Industry Key biotechnology
Earnings Growth -38.00 % Enterprise To Revenue -0.7550 Revenue Growth 17.60 %
Shares Percent Shares Out 0.0036 Operating Cashflow 6 B Currency USD
Time Zone Full Name America/New_York Market Cap 13 B Is_nasdaq_100 False
Zip 2500 Quote Type EQUITY Industry Biotechnology
Long Name Genmab A/S Regular Market Day Low 20.84 Held Percent Institutions 0.0840
Current Price 21.16 Address2 Valby Enterprise To Ebitda -2.19
Financial Currency DKK Current Ratio 5.17 Gross Margins 96.10 %
Industry Disp Biotechnology Number Of Analyst Opinions 9 Country Denmark
Float Shares 62 M Two Hundred Day Average 26.78 Ir Website http://ir.genmab.com/index.cfm
Enterprise Value -14987052032 Price To Sales Trailing12 Months 0.6773 Forward PE 13.39
Regular Market Volume 785831 Ebitda 6 B Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.

The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.

In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease.

It operates various active pre-clinical programs.

The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin.

It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S.

Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.